Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial

Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics

Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in GA

Cognition Therapeutics reported topline results from the Phase 2 COG2201 ‘MAGNIFY’ trial of zervimesine (CT1812) in adults with geographic atrophy (GA). The results show zervimesine-treated participants had 28.6% slower GA lesion growth on average and at 18 months, and their lesions were 28.2% smaller compared to placebo. The MAGNIFY study (NCT05893537) was concluded after approximately 100 of the planned 246 participants were enrolled. “To date…

Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial

Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.